Menu Search
Equities

RaySearch Laboratories AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert
27R:STU

RaySearch Laboratories AB (publ)

Actions
  • Price (EUR)16.80
  • Today's Change-0.50 / -2.89%
  • Shares traded0.00
  • 1 Year change-24.15%
  • Beta1.0133
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

RaySearch Laboratories AB (publ) is a Sweden-based medical technology company that develops software for radiation therapy of cancer. It markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.

  • Revenue in SEK (TTM)1.29bn
  • Net income in SEK219.17m
  • Incorporated1988
  • Employees450.00
  • Location
    RaySearch Laboratories AB (publ)Eugeniavagen 18CSTOCKHOLM 104 30SwedenSWE
  • Phone+46 851053000
  • Fax+46 854506139
  • Websitehttps://www.raysearchlabs.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.